WORLDCOIN-FOUNDATION
15.5.2024 15:03:34 CEST | Business Wire | Press release
The Worldcoin Foundation today announced it launched and is open sourcing a novel secure multi-party computation (SMPC) system. The system, available now in a GitHub repository for any organization to use, aims to set a new standard for data protection, including the protection of biometric data. The Worldcoin Foundation also announced that, after the migration of iris codes to the new SMPC system, the previous uniqueness-checking system, including iris codes, was securely deleted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515285506/en/
Worldcoin Foundation Launches, Open Sources "Perfect Secrecy" SMPC System to Help Organizations Strengthen Biometric Data Security Protections (Graphic: Business Wire)
Biometric authentication use increases as data breach frequency and impact rise
Organizations in the private and public sector increasingly require and use consumers’ biometric data for everyday services and activities, from building access and airport security to logging into healthcare and financial services apps. Underscoring the increase, a Fortune Business Insights report projected the global biometric system market size to reach $76.70 billion USD in 2029, 2.5x its total of $30.77 billion in 2022.
Meanwhile, research from MIT Professor Stuart Madnick indicates a 20% increase in data breaches from 2022 to 2023 while globally the number of victims of such breaches doubled over the same time period.
The convergence of these trends suggests a need to further advance data protection technologies. While Worldcoin is neither an authentication nor an identification use case for biometrics (the Worldcoin Foundation does not know the identity of their users), the Foundation’s new open source SMPC system can serve as a building block to set a new standard in biometric data security.
Worldcoin Foundation’s SMPC system
SMPC has been lauded by privacy and security experts alike. It can be thought of as taking one secret and sharing it in multiple parts across different parties for increased protection. Importantly, none of the individual parts alone say anything about the original secret, thus making it impossible for any individual party to decrypt the secret.
This SMPC approach demonstrates perfect information-theoretic security, meaning it is effective even against quantum-computing. SMPC systems have generally been too resource-intensive to be effectively used for large complex computations. This is why, despite their impressive privacy protective qualities, they have not yet seen extensive use in biometric template protection.
The Worldcoin Foundation, along with contributor-technologists from TACEO and Tools for Humanity, have successfully architected a new implementation of SMPC to address the scale and cost constraints that have previously hindered others. The new SMPC system, which encrypts iris codes into secret shares held by multiple parties, enabled the Worldcoin Foundation to permanently delete iris codes generated through its previous uniqueness-checking system.
“The community supporting Worldcoin will never stop developing, testing and deploying the most advanced technologies focusing on security, privacy and data protection as it works to improve trust online and increase access to the global economy,” said Jannick Preiwisch, Data Protection Officer of the Worldcoin Foundation. “Implementation of the new SMPC system enabled the Worldcoin Foundation to delete old iris codes by permanently encrypting them to SMPC shares that by themselves cannot be related to an identified person. The development of this new system demonstrates an unparalleled commitment to further compliance with the EU General Data Protection Regulation and other data protection regimes across the world. It also complements advancements aimed at providing consumers increased choice and control over their data including personal custody and the ability to unverify their World IDs.”
About the Worldcoin Foundation
The Worldcoin Foundation, a steward of the Worldcoin protocol, aims to realize more inclusive, fair and just institutions of governance and of the global digital economy.
About the Worldcoin Protocol
The Worldcoin protocol is intended to be the world’s largest, most inclusive identity and financial public utility and to be accessible by everyone. Worldcoin was originally conceived by Sam Altman, Alex Blania and Max Novendstern. The Worldcoin protocol is designed to empower individuals and organizations around the world with the tools they need to participate in the digital economy and advance humanity's progress. Find out more about Worldcoin at www.worldcoin.org, on Twitter/X, Discord, YouTube and Telegram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515285506/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
